Recent DNLI News
- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 03/01/2024 09:51:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:07:37 PM
- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights • GlobeNewswire Inc. • 02/27/2024 01:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:03:38 PM
- Denali Therapeutics Announces $500 million Private Placement Equity Financing • GlobeNewswire Inc. • 02/27/2024 01:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:02:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:15:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:14:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:14:01 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:59:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:43:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 01:19:50 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 01:18:42 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 01:17:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:48:27 PM
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™ • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™ • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 01:18:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 10:28:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/10/2024 09:09:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:35:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:34:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:33:21 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/10/2024 12:20:52 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM